Eli O. Meltzer, MD, Don A. Bukstein, MD, Paul M. Hamrah, MS, PharmD, Nikkia Scott, PharmD, John A. Welz, MPH
Sarilumab (Kevzara) is a novel interleukin (IL)-6 receptor inhibitor that was approved by the US Food and Drug Administration (FDA) on May 22, 2017, for the treatment of adults with moderately or severely active RA who have had an inadequate response or intolerance to 1 or more DMARDs.
Approximately 75% of breast cancers rely on ER signaling to grow and survive.2 Endocrine therapy, which blocks the growth-promoting activity of estrogen, represents the primary intervention for early- and advanced-stage ER-positive breast cancer.3 However, some patients do not respond to endocrine therapy (ie, de novo resistance), and some patients who initially respond to therapy have disease that progresses during therapy (ie, acquired resistance).3
An increased understanding of the molecular pathogenesis of RA has led to significant advances in biologic therapies in the past 15 years and has dramatically changed the treatment paradigm for RA.3 Currently, 4 classes of biologic DMARDs are available, including (1) the tumor necrosis factor (TNF)-α inhibitors adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab; (2) abatacept, which blocks T-cell costimulation via anti-CD80/86 inhibition; (3) the anti-CD20 agent that causes B-cell depletion, rituximab; and (4) the interleukin (IL)-6 receptor (IL-6R) blocker, tocilizumab.
￼A Multidisciplinary Approach to the Treatment of Prostate Cancer: Providing Therapies That Improve Overall Survival and Quality of Life
Faculty Perspectives in Chronic Pain:Utilizing Pharmacogenomics When Selecting Personalized Medicine for Patients with Chronic Pain
Faculty Perspectives: Similarities and Differences in Agitation Associated with Schizophrenia and Bipolar Disorder
Faculty Perspectives: Coping with Agitation Associated with Schizophrenia and Bipolar Disorder: How Can Healthcare Professionals Help Their Patients?
Agitation refers to a spectrum of abnormal behaviors frequently seen in patients with psychiatric illnesses, including in individuals with schizophrenia or bipolar disorder. It is a mental and physical state that is characterized by motor restlessness, mental tension, and excitement, and it is often marked by poorly organized, aimless psychomotor activity. Agitated patients may exhibit aggressive behavior, resulting in harm to themselves, other patients, and healthcare workers. Therefore, prompt and effective management of agitation is critically important in the care of schizophrenia or bipolar disorder, and it requires the skills and expertise of several types of professionals. Typically, both pharmacologic and nonpharmacologic strategies are necessary to achieve optimal results.
Page 1 of 5
Results 1 - 10 of 43
Results 1 - 10 of 43